{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:49:17Z","timestamp":1785761357945,"version":"3.56.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41585-026-01129-8","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:02:46Z","timestamp":1770656566000},"page":"533-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ADT and activation of HGF and WNT axes in double-null prostate cancer"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-8131","authenticated-orcid":false,"given":"Dexter Hoi Long","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao Mawulikplimi","family":"Adzavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3843-6393","authenticated-orcid":false,"given":"Gaeul","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5245-1753","authenticated-orcid":false,"given":"Tae Ju","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Nikias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheong-Wun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenmiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"1129_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030361","volume":"8","author":"CH Pernar","year":"2018","unstructured":"Pernar, C. H., Ebot, E. M., Wilson, K. M. & Mucci, L. A. The epidemiology of prostate cancer. Cold Spring Harb. Perspect. Med. 8, a030361\u00a0(2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1129_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","volume":"25","author":"CA Heinlein","year":"2004","unstructured":"Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276\u2013308 (2004).","journal-title":"Endocr. Rev."},{"key":"1129_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","volume":"168","author":"C Huggins","year":"2002","unstructured":"Huggins, C. & Hodges, C. V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168, 9\u201312 (2002).","journal-title":"J. Urol."},{"key":"1129_CR4","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar, T., Yang, J. C., Gao, A. C. & Evans, C. P. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl. Androl. Urol. 4, 365\u2013380 (2015).","journal-title":"Transl. Androl. Urol."},{"key":"1129_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"A Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga, A. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360\u2013371 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1129_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34\u201345 (2001).","journal-title":"Nat. Rev. Cancer"},{"key":"1129_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06067-7","volume":"9","author":"Q Li","year":"2018","unstructured":"Li, Q. et al. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat. Commun. 9, 3600 (2018).","journal-title":"Nat. Commun."},{"key":"1129_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","volume":"22","author":"JE Vellky","year":"2020","unstructured":"Vellky, J. E. & Ricke, W. A. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia 22, 566\u2013575 (2020).","journal-title":"Neoplasia"},{"key":"1129_CR9","first-page":"228","volume":"19","author":"PI Velho","year":"2021","unstructured":"Velho, P. I., Bastos, D. A. & Antonarakis, E. S. New approaches to targeting the androgen receptor pathway in prostate cancer. Clin. Adv. Hematol. Oncol. 19, 228\u2013240 (2021). This review elucidates the evolution of AR targeting in clinical management for patients with prostate cancer and, specifically, summarizes the clinical outcomes of the new therapeutic agents, such as abiraterone, enzalutamide, apalutamide and darolutamide, in different disease states.","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"1129_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474\u2013489.e6 (2017). This study reports the new subtype of CRPC with AR-null and neuroendocrine-null cell properties, termed \u2018double-null\u2019 prostate cancer. Additionally, the study demonstrates the regulatory role of FGF signalling in the pathogenesis of DNPC.","journal-title":"Cancer Cell"},{"key":"1129_CR11","doi-asserted-by":"publisher","first-page":"T51","DOI":"10.1530\/ERC-21-0002","volume":"28","author":"MP Labrecque","year":"2021","unstructured":"Labrecque, M. P., Alumkal, J. J., Coleman, I. M., Nelson, P. S. & Morrissey, C. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Endocr. Relat. Cancer 28, T51\u2013T66 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"1129_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.path.2024.10.003","volume":"18","author":"GN Fanelli","year":"2025","unstructured":"Fanelli, G. N., Nuzzo, P. V., Pederzoli, F. & Loda, M. Deciphering complexity: the molecular landscape of castration-resistant prostate cancer. Surg. Pathol. Clin. 18, 25\u201339 (2025).","journal-title":"Surg. Pathol. Clin."},{"key":"1129_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.ccell.2025.04.002","volume":"43","author":"J Guo","year":"2025","unstructured":"Guo, J. et al. KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy. Cancer Cell 43, 1261\u20131278.e10 (2025).","journal-title":"Cancer Cell"},{"key":"1129_CR14","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","volume":"83","author":"A Lundberg","year":"2023","unstructured":"Lundberg, A. et al. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. Cancer Res. 83, 2763\u20132774 (2023).","journal-title":"Cancer Res."},{"key":"1129_CR15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415308122","volume":"122","author":"SP Pitzen","year":"2025","unstructured":"Pitzen, S. P. et al. Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 122, e2415308122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1129_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187490","volume":"135","author":"Z Duan","year":"2025","unstructured":"Duan, Z. et al. PROX1 is an early driver of lineage plasticity in prostate cancer. J. Clin. Invest. 135, e187490\u00a0(2025).","journal-title":"J. Clin. Invest."},{"key":"1129_CR17","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428\u201311436 (2019). In this study, 429 metastatic castration-resistant prostate cancer samples are analysed. Results from this study provide the information regarding the next generation of AR inhibitors, suggesting how molecular heterogeneity influences treatment response and survival.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1129_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107669","volume":"31","author":"MD Nyquist","year":"2020","unstructured":"Nyquist, M. D. et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 31, 107669 (2020).","journal-title":"Cell Rep."},{"key":"1129_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45489-4","volume":"15","author":"WK Kim","year":"2024","unstructured":"Kim, W. K. et al. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation. Nat. Commun. 15, 1231 (2024). In this study, current ADT is shown to induce HGF\u2013MET signalling activation, which subsequently elevates WNT\u2013\u03b2-catenin pathways in clinical DNPC. Co-activation of both HGF\u2013MET and WNT\u2013\u03b2-catenin signalling pathways in mouse prostate tissues causes the development of DNPC-like tumour lesions in mice. The upregulation of XPO1 and ribosomal proteins is identified in both human and mouse DNPC cells. Inhibition of XPO1 and ribosomal protein activities substantially represses DNPC growth in in vivo and ex vivo approaches.","journal-title":"Nat. Commun."},{"key":"1129_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian, N. G. & Li, Y. XPO1-dependent nuclear export as a target for cancer therapy. J. Hematol. Oncol. 13, 61 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1129_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi, A. S., Uddin, M. H. & Mohammad, R. M. The nuclear export protein XPO1 \u2014 from biology to targeted therapy. Nat. Rev. Clin. Oncol. 18, 152\u2013169 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1129_CR22","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.21037\/tcr-21-1646","volume":"10","author":"L Zhao","year":"2021","unstructured":"Zhao, L. et al. Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis. Transl. Cancer Res. 10, 4664\u20134679 (2021).","journal-title":"Transl. Cancer Res."},{"key":"1129_CR23","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A. & Samant, R. S. Ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance. Cancer Res. 82, 2344\u20132353 (2022).","journal-title":"Cancer Res."},{"key":"1129_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier, J., Thomas, G. & Volarevic, S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat. Rev. Cancer 18, 51\u201363 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1129_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10","author":"J van Riggelen","year":"2010","unstructured":"van Riggelen, J., Yetil, A. & Felsher, D. W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 10, 301\u2013309 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"1129_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116332","volume":"226","author":"G Temaj","year":"2024","unstructured":"Temaj, G. et al. P53: a key player in diverse cellular processes including nuclear stress and ribosome biogenesis, highlighting potential therapeutic compounds. Biochem. Pharmacol. 226, 116332 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"1129_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2353\/ajpath.2008.070752","volume":"173","author":"L Montanaro","year":"2008","unstructured":"Montanaro, L., Trere, D. & Derenzini, M. Nucleolus, ribosomes, and cancer. Am. J. Pathol. 173, 301\u2013310 (2008).","journal-title":"Am. J. Pathol."},{"key":"1129_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrc1274","volume":"4","author":"TR Kau","year":"2004","unstructured":"Kau, T. R., Way, J. C. & Silver, P. A. Nuclear transport and cancer: from mechanism to intervention. Nat. Rev. Cancer 4, 106\u2013117 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"1129_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","volume":"83","author":"JG Turner","year":"2012","unstructured":"Turner, J. G., Dawson, J. & Sullivan, D. M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 83, 1021\u20131032 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"1129_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcdb.2017.05.006","volume":"68","author":"S Sakuma","year":"2017","unstructured":"Sakuma, S. & D\u2019Angelo, M. A. The roles of the nuclear pore complex in cellular dysfunction, aging and disease. Semin. Cell Dev. Biol. 68, 72\u201384 (2017).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1129_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-20-0581","volume":"11","author":"S Sakuma","year":"2021","unstructured":"Sakuma, S. et al. Inhibition of nuclear pore complex formation selectively induces cancer cell death. Cancer Discov. 11, 176\u2013193 (2021).","journal-title":"Cancer Discov."},{"key":"1129_CR32","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cell.2018.07.015","volume":"174","author":"V Rodriguez-Bravo","year":"2018","unstructured":"Rodriguez-Bravo, V. et al. Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import. Cell 174, 1200\u20131215.e20 (2018).","journal-title":"Cell"},{"key":"1129_CR33","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/leu.2016.19","volume":"30","author":"VP Lavallee","year":"2016","unstructured":"Lavallee, V. P. et al. Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations. Leukemia 30, 1621\u20131624 (2016).","journal-title":"Leukemia"},{"key":"1129_CR34","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.dld.2022.02.008","volume":"54","author":"C Gan","year":"2022","unstructured":"Gan, C. et al. NUP153 promotes HCC cells proliferation via c-Myc-mediated downregulation of P15(INK4b). Dig. Liver Dis. 54, 1706\u20131715 (2022).","journal-title":"Dig. Liver Dis."},{"key":"1129_CR35","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1101\/gad.314377.118","volume":"32","author":"Y Su","year":"2018","unstructured":"Su, Y. et al. Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev. 32, 1398\u20131419 (2018).","journal-title":"Genes Dev."},{"key":"1129_CR36","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1210\/mend-5-10-1396","volume":"5","author":"G Jenster","year":"1991","unstructured":"Jenster, G. et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 5, 1396\u20131404 (1991).","journal-title":"Mol. Endocrinol."},{"key":"1129_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1210\/endo-122-2-552","volume":"122","author":"N Kyprianou","year":"1988","unstructured":"Kyprianou, N. & Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122, 552\u2013562 (1988).","journal-title":"Endocrinology"},{"key":"1129_CR38","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1101\/gad.819500","volume":"14","author":"C Abate-Shen","year":"2000","unstructured":"Abate-Shen, C. & Shen, M. M. Molecular genetics of prostate cancer. Genes Dev. 14, 2410\u20132434 (2000).","journal-title":"Genes Dev."},{"key":"1129_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semcancer.2021.06.016","volume":"82","author":"W Li","year":"2022","unstructured":"Li, W. & Shen, M. M. Prostate cancer cell heterogeneity and plasticity: Insights from studies of genetically-engineered mouse models. Semin. Cancer Biol. 82, 60\u201367 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1129_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33\u201339 (2004).","journal-title":"Nat. Med."},{"key":"1129_CR41","first-page":"314","volume":"57","author":"P Koivisto","year":"1997","unstructured":"Koivisto, P. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314\u2013319 (1997).","journal-title":"Cancer Res."},{"key":"1129_CR42","first-page":"735","volume":"144","author":"JA Ruizeveld de Winter","year":"1994","unstructured":"Ruizeveld de Winter, J. A. et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 144, 735\u2013746 (1994).","journal-title":"Am. J. Pathol."},{"key":"1129_CR43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"1129_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769.e9 (2018).","journal-title":"Cell"},{"key":"1129_CR45","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","volume":"332","author":"ME Taplin","year":"1995","unstructured":"Taplin, M. E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393\u20131398 (1995).","journal-title":"N. Engl. J. Med."},{"key":"1129_CR46","first-page":"2861","volume":"54","author":"JP Gaddipati","year":"1994","unstructured":"Gaddipati, J. P. et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54, 2861\u20132864 (1994).","journal-title":"Cancer Res."},{"key":"1129_CR47","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo, Z. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305\u20132313 (2009).","journal-title":"Cancer Res."},{"key":"1129_CR48","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","volume":"15","author":"A Paschalis","year":"2018","unstructured":"Paschalis, A. et al. Alternative splicing in prostate cancer. Nat. Rev. Clin. Oncol. 15, 663\u2013675 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1129_CR49","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/JU.0000000000002923","volume":"208","author":"M Rouleau","year":"2022","unstructured":"Rouleau, M. et al. Extensive alteration of androgen precursor levels after castration in prostate cancer patients and their association with active androgen level. J. Urol. 208, 1214\u20131225 (2022).","journal-title":"J. Urol."},{"key":"1129_CR50","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41585-024-00878-8","volume":"21","author":"M Bitaraf","year":"2024","unstructured":"Bitaraf, M., Ramasamy, R., Punnen, S. & Sharifi, N. Elevated periprostatic androgens, sneaky testosterone and its implications. Nat. Rev. Urol. 21, 754\u2013760 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"1129_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s002400000111","volume":"28","author":"Z Culig","year":"2000","unstructured":"Culig, Z., Hobisch, A., Bartsch, G. & Klocker, H. Androgen receptor \u2014 an update of mechanisms of action in prostate cancer. Urol. Res. 28, 211\u2013219 (2000).","journal-title":"Urol. Res."},{"key":"1129_CR52","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/01.ju.0000075099.20662.7f","volume":"170","author":"Z Culig","year":"2003","unstructured":"Culig, Z., Klocker, H., Bartsch, G., Steiner, H. & Hobisch, A. Androgen receptors in prostate cancer. J. Urol. 170, 1363\u20131369 (2003).","journal-title":"J. Urol."},{"key":"1129_CR53","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1158\/1078-0432.CCR-04-0738","volume":"11","author":"MA Titus","year":"2005","unstructured":"Titus, M. A. et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11, 4365\u20134371 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1129_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"1129_CR55","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916\u20136924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1129_CR56","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrm1261","volume":"4","author":"C Birchmeier","year":"2003","unstructured":"Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915\u2013925 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1129_CR57","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/oxfordjournals.jbchem.a021283","volume":"119","author":"K Matsumoto","year":"1996","unstructured":"Matsumoto, K. & Nakamura, T. Emerging multipotent aspects of hepatocyte growth factor. J. Biochem. 119, 591\u2013600 (1996).","journal-title":"J. Biochem."},{"key":"1129_CR58","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1126\/science.1846706","volume":"251","author":"DP Bottaro","year":"1991","unstructured":"Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802\u2013804 (1991).","journal-title":"Science"},{"key":"1129_CR59","first-page":"386","volume":"147","author":"PA Humphrey","year":"1995","unstructured":"Humphrey, P. A. et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147, 386\u2013396 (1995).","journal-title":"Am. J. Pathol."},{"key":"1129_CR60","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1006\/bbrc.1996.1710","volume":"228","author":"S Kasai","year":"1996","unstructured":"Kasai, S. et al. Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth. Biochem. Biophys. Res. Commun. 228, 646\u2013652 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1129_CR61","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0090-4295(02)01954-4","volume":"60","author":"BS Knudsen","year":"2002","unstructured":"Knudsen, B. S. et al. High expression of the met receptor in prostate cancer metastasis to bone. Urology 60, 1113\u20131117 (2002). An increase in MET expression in metastatic prostate cancer specimens is to our knowledge first reported in this article. Importantly, significantly higher MET expression is observed in bone metastases than in lymph node metastases, suggesting a specific role of MET in prostate cancer bone metastasis. Given that the bone microenvironment is enriched in HGF, this observation suggests a regulatory mechanism for MET in the pathogenesis of bone metastasis. Additionally, in the context of ADT, elevated MET expression in bone metastases further suggests that HGF\u2013MET activation is a compensatory, AR-independent pathway that promotes metastatic potential and therapeutic resistance.","journal-title":"Urology"},{"key":"1129_CR62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0022-5347(01)67297-5","volume":"154","author":"LL Pisters","year":"1995","unstructured":"Pisters, L. L. et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154, 293\u2013298 (1995).","journal-title":"J. Urol."},{"key":"1129_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0090-4295(03)00758-1","volume":"62","author":"JA Schalken","year":"2003","unstructured":"Schalken, J. A. & van Leenders, G. Cellular and molecular biology of the prostate: stem cell biology. Urology 62, 11\u201320 (2003).","journal-title":"Urology"},{"key":"1129_CR64","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/pros.10073","volume":"51","author":"G van Leenders","year":"2002","unstructured":"van Leenders, G. et al. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 51, 98\u2013107 (2002).","journal-title":"Prostate"},{"key":"1129_CR65","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0304-3835(99)00102-0","volume":"141","author":"M Watanabe","year":"1999","unstructured":"Watanabe, M. et al. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett. 141, 173\u2013178 (1999).","journal-title":"Cancer Lett."},{"key":"1129_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026753","volume":"6","author":"GJ van Leenders","year":"2011","unstructured":"van Leenders, G. J. et al. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS ONE 6, e26753 (2011).","journal-title":"PLoS ONE"},{"key":"1129_CR67","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/1078-0432.CCR-09-0599","volume":"15","author":"AL Russo","year":"2009","unstructured":"Russo, A. L. et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin. Cancer Res. 15, 4292\u20134298 (2009).","journal-title":"Clin. Cancer Res."},{"key":"1129_CR68","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/pros.21473","volume":"72","author":"M Colombel","year":"2012","unstructured":"Colombel, M. et al. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 72, 713\u2013720 (2012).","journal-title":"Prostate"},{"key":"1129_CR69","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1517\/13543784.2011.631523","volume":"20","author":"A Varkaris","year":"2011","unstructured":"Varkaris, A. et al. The role of HGF\/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin. Investig. Drugs 20, 1677\u20131684 (2011).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1129_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11\u201322 (2010).","journal-title":"Cancer Cell"},{"key":"1129_CR71","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/0008-5472.CAN-06-3552","volume":"67","author":"M Verras","year":"2007","unstructured":"Verras, M. et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 67, 967\u2013975 (2007). In this study, AR is shown to repress MET expression in prostate cancer cells through a ligand-dependent mechanism by interfering with SP1-induced transcription at the MET promoter. The results demonstrate a dual role for AR in transcriptional regulation, suggesting that ADT, although suppressing AR-activated genes, could inadvertently enhance MET expression.","journal-title":"Cancer Res."},{"key":"1129_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-556","volume":"10","author":"WH Tu","year":"2010","unstructured":"Tu, W. H., Zhu, C., Clark, C., Christensen, J. G. & Sun, Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 10, 556 (2010).","journal-title":"BMC Cancer"},{"key":"1129_CR73","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3892\/ijo.2013.2020","volume":"43","author":"T Liu","year":"2013","unstructured":"Liu, T., Mendes, D. E. & Berkman, C. E. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int. J. Oncol. 43, 1125\u20131130 (2013).","journal-title":"Int. J. Oncol."},{"key":"1129_CR74","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11523-015-0412-7","volume":"11","author":"A Modena","year":"2016","unstructured":"Modena, A. et al. Targeting Met and VEGFR axis in metastatic castration-resistant prostate cancer: \u2018Game over\u2019? Target. Oncol. 11, 431\u2013446 (2016).","journal-title":"Target. Oncol."},{"key":"1129_CR75","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1541-7786.MCR-24-0395","volume":"22","author":"SH Choi","year":"2024","unstructured":"Choi, S. H. et al. Characterization of Wnt signaling pathway aberrations in metastatic prostate cancer. Mol. Cancer Res. 22, 920\u2013931 (2024).","journal-title":"Mol. Cancer Res."},{"key":"1129_CR76","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2890","volume":"18","author":"Y Sun","year":"2012","unstructured":"Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359\u20131368 (2012).","journal-title":"Nat. Med."},{"key":"1129_CR77","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/path.1449","volume":"201","author":"C Wissmann","year":"2003","unstructured":"Wissmann, C. et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J. Pathol. 201, 204\u2013212 (2003).","journal-title":"J. Pathol."},{"key":"1129_CR78","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/0008-5472.CAN-21-1807","volume":"82","author":"F Ma","year":"2022","unstructured":"Ma, F. et al. Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer. Cancer Res. 82, 1518\u20131533 (2022).","journal-title":"Cancer Res."},{"key":"1129_CR79","doi-asserted-by":"publisher","first-page":"8453","DOI":"10.1038\/sj.onc.1206049","volume":"21","author":"DR Chesire","year":"2002","unstructured":"Chesire, D. R. & Isaacs, W. B. Ligand-dependent inhibition of beta-catenin\/TCF signaling by androgen receptor. Oncogene 21, 8453\u20138469 (2002).","journal-title":"Oncogene"},{"key":"1129_CR80","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1038\/sj.onc.1206426","volume":"22","author":"B Bierie","year":"2003","unstructured":"Bierie, B. et al. Activation of \u03b2-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22, 3875\u20133887 (2003).","journal-title":"Oncogene"},{"key":"1129_CR81","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/sj.onc.1205562","volume":"21","author":"F Gounari","year":"2002","unstructured":"Gounari, F. et al. Stabilization of \u03b2-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21, 4099\u20134107 (2002).","journal-title":"Oncogene"},{"key":"1129_CR82","doi-asserted-by":"publisher","first-page":"17933","DOI":"10.1074\/jbc.M200135200","volume":"277","author":"DJ Mulholland","year":"2002","unstructured":"Mulholland, D. J., Cheng, H., Reid, K., Rennie, P. S. & Nelson, C. C. The androgen receptor can promote \u03b2-catenin nuclear translocation independently of adenomatous polyposis coli. J. Biol. Chem. 277, 17933\u201317943 (2002).","journal-title":"J. Biol. Chem."},{"key":"1129_CR83","doi-asserted-by":"publisher","first-page":"11336","DOI":"10.1074\/jbc.M111962200","volume":"277","author":"F Yang","year":"2002","unstructured":"Yang, F. et al. Linking \u03b2-catenin to androgen-signaling pathway. J. Biol. Chem. 277, 11336\u201311344 (2002).","journal-title":"J. Biol. Chem."},{"key":"1129_CR84","first-page":"4709","volume":"60","author":"CI Truica","year":"2000","unstructured":"Truica, C. I., Byers, S. & Gelmann, E. P. \u03b2-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60, 4709\u20134713 (2000).","journal-title":"Cancer Res."},{"key":"1129_CR85","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/onc.2015.117","volume":"35","author":"SH Lee","year":"2016","unstructured":"Lee, S. H. et al. Androgen signaling is a confounding factor for \u03b2-catenin-mediated prostate tumorigenesis. Oncogene 35, 702\u2013714 (2016).","journal-title":"Oncogene"},{"key":"1129_CR86","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-3-030-32656-2_16","volume":"1210","author":"Y Yeh","year":"2019","unstructured":"Yeh, Y. et al. Wnt\/beta-catenin signaling and prostate cancer therapy resistance. Adv. Exp. Med. Biol. 1210, 351\u2013378 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1129_CR87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ccr.2013.01.002","volume":"23","author":"J Weischenfeldt","year":"2013","unstructured":"Weischenfeldt, J. et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159\u2013170 (2013).","journal-title":"Cancer Cell"},{"key":"1129_CR88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","volume":"77","author":"P Isaacsson Velho","year":"2020","unstructured":"Isaacsson Velho, P. et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur. Urol. 77, 14\u201321 (2020).","journal-title":"Eur. Urol."},{"key":"1129_CR89","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/763569","volume":"2013","author":"BD Wang","year":"2013","unstructured":"Wang, B. D. et al. Androgen receptor-target genes in African American prostate cancer disparities. Prostate Cancer 2013, 763569 (2013).","journal-title":"Prostate Cancer"},{"key":"1129_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32119-0","volume":"13","author":"WK Kim","year":"2022","unstructured":"Kim, W. K. et al. Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes. Nat. Commun. 13, 4364 (2022). In this study, AR is shown to have an inducible role in activating IGF1 and WNT\u2013\u03b2-catenin pathways and initiating prostate oncogenesis. Additionally, the results of this study show that co-inhibition of androgen and WNT signalling pathways significantly suppresses AR-positive tumour cell growth both ex vivo and in vivo, suggesting a promising co-targeting therapeutic strategy for advanced prostate cancer.","journal-title":"Nat. Commun."},{"key":"1129_CR91","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1210\/me.2006-0021","volume":"20","author":"MA Albertelli","year":"2006","unstructured":"Albertelli, M. A., Scheller, A., Brogley, M. & Robins, D. M. Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol. Endocrinol. 20, 1248\u20131260 (2006).","journal-title":"Mol. Endocrinol."},{"key":"1129_CR92","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1038\/s41388-020-1214-7","volume":"39","author":"Y He","year":"2020","unstructured":"He, Y. et al. Androgen receptor with short polyglutamine tract preferably enhances Wnt\/\u03b2-catenin-mediated prostatic tumorigenesis. Oncogene 39, 3276\u20133291 (2020).","journal-title":"Oncogene"},{"key":"1129_CR93","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-07-6289","volume":"68","author":"VR Placencio","year":"2008","unstructured":"Placencio, V. R. et al. Stromal transforming growth factor-\u03b2 signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res. 68, 4709\u20134718 (2008).","journal-title":"Cancer Res."},{"key":"1129_CR94","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1158\/0008-5472.CAN-20-3543","volume":"81","author":"HJ Li","year":"2021","unstructured":"Li, H. J. et al. ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-to-mesenchymal transition. Cancer Res. 81, 4094\u20134109 (2021).","journal-title":"Cancer Res."},{"key":"1129_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08955-6","volume":"21","author":"C Giacomelli","year":"2021","unstructured":"Giacomelli, C. et al. Coordinated regulation of WNT\/\u03b2-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits. BMC Cancer 21, 1296 (2021).","journal-title":"BMC Cancer"},{"key":"1129_CR96","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1074\/jbc.RA119.011137","volume":"295","author":"J Aldahl","year":"2020","unstructured":"Aldahl, J. et al. Aberrant activation of hepatocyte growth factor\/MET signaling promotes \u03b2-catenin-mediated prostatic tumorigenesis. J. Biol. Chem. 295, 631\u2013644 (2020).","journal-title":"J. Biol. Chem."},{"key":"1129_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02033-1","volume":"23","author":"Y Xia","year":"2025","unstructured":"Xia, Y. et al. Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: implications for counteracting tumor immune evasion. Cell Commun. Signal. 23, 46 (2025).","journal-title":"Cell Commun. Signal."},{"key":"1129_CR98","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1210\/me.2014-1078","volume":"28","author":"Y Xie","year":"2014","unstructured":"Xie, Y. et al. Crosstalk between nuclear MET and SOX9\/\u03b2-catenin correlates with castration-resistant prostate cancer. Mol. Endocrinol. 28, 1629\u20131639 (2014).","journal-title":"Mol. Endocrinol."},{"key":"1129_CR99","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353\u2013357 (2015).","journal-title":"Nature"},{"key":"1129_CR100","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.prp.2018.04.015","volume":"214","author":"M Sainio","year":"2018","unstructured":"Sainio, M., Visakorpi, T., Tolonen, T., Ilvesaro, J. & Bova, G. S. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathol. Res. Pract. 214, 848\u2013856 (2018).","journal-title":"Pathol. Res. Pract."},{"key":"1129_CR101","doi-asserted-by":"publisher","first-page":"35327","DOI":"10.18632\/oncotarget.26239","volume":"9","author":"A Aboukameel","year":"2018","unstructured":"Aboukameel, A. et al. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget 9, 35327\u201335342 (2018).","journal-title":"Oncotarget"},{"key":"1129_CR102","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae029","volume":"6","author":"S Ramalho","year":"2024","unstructured":"Ramalho, S., Dopler, A. & Faller, W. J. Ribosome specialization in cancer: a spotlight on ribosomal proteins. NAR Cancer 6, zcae029 (2024).","journal-title":"NAR Cancer"},{"key":"1129_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186047","volume":"12","author":"C Arthurs","year":"2017","unstructured":"Arthurs, C. et al. Expression of ribosomal proteins in normal and cancerous human prostate tissue. PLoS ONE 12, e0186047 (2017).","journal-title":"PLoS ONE"},{"key":"1129_CR104","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211577","volume":"41","author":"W El Khoury","year":"2021","unstructured":"El Khoury, W. & Nasr, Z. Deregulation of ribosomal proteins in human cancers. Biosci. Rep. 41, BSR20211577\u00a0(2021).","journal-title":"Biosci. Rep."},{"key":"1129_CR105","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang, J. et al. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct. Target. Ther. 6, 323 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1129_CR106","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","volume":"77","author":"S Gillessen","year":"2020","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur. Urol. 77, 508\u2013547 (2020).","journal-title":"Eur. Urol."},{"key":"1129_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101179","volume":"14","author":"JC Rosen","year":"2021","unstructured":"Rosen, J. C. et al. Antitumor efficacy of XPO1 inhibitor selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. Transl. Oncol. 14, 101179 (2021).","journal-title":"Transl. Oncol."},{"key":"1129_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30686-1","volume":"8","author":"VV Subhash","year":"2018","unstructured":"Subhash, V. V. et al. Anti-tumor efficacy of selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci. Rep. 8, 12248 (2018).","journal-title":"Sci. Rep."},{"key":"1129_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70076","volume":"13","author":"Y Han","year":"2024","unstructured":"Han, Y. et al. XPO1 serves as a prognostic marker involving AKT\/MAPK\/TGFBR1 pathway in OSCC. Cancer Med. 13, e70076 (2024).","journal-title":"Cancer Med."},{"key":"1129_CR110","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1200\/JCO.22.02906","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote, I. et al. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J. Clin. Oncol. 41, 5400\u20135410 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1129_CR111","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1634\/theoncologist.2017-0624","volume":"23","author":"XX Wei","year":"2018","unstructured":"Wei, X. X. et al. A phase II trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and\/or enzalutamide-refractory metastatic castration-resistant prostate cancer. Oncologist 23, 656\u2013e664 (2018). This phase II study presents the first line of clinical evidence demonstrating the effect of selinexor, the FDA-approved XPO1 inhibitor, in treating patients with mCRPC who received second-generation anti-androgen therapies. Unfortunately, selinexor shows considerable toxic effects, including anorexia, nausea, weight loss, fatigue and thrombocytopenia, ultimately limiting its further clinical use in this patient population.","journal-title":"Oncologist"},{"key":"1129_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62852-z","volume":"14","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Adverse events reporting of XPO1 inhibitor \u2014 selinexor: a real-word analysis from FAERS database. Sci. Rep. 14, 12231 (2024). In this study, 4392 selinexor-related adverse event reports from the FDA Adverse Event Reporting System over a 4-year period (2019\u20132023) are analysed, revealing that 59% result in severe outcomes. These real-world findings provide crucial evidence for clinicians to better monitor and manage patients receiving selinexor therapy across various oncological indications.","journal-title":"Sci. Rep."},{"key":"1129_CR113","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/leu.2016.145","volume":"31","author":"J Etchin","year":"2017","unstructured":"Etchin, J. et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia 31, 143\u2013150 (2017).","journal-title":"Leukemia"},{"key":"1129_CR114","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.2019.37.7_suppl.197","volume":"37","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 37, 197\u2013197 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1129_CR115","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1002\/ajh.26420","volume":"97","author":"RF Cornell","year":"2022","unstructured":"Cornell, R. F. et al. A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. Am. J. Hematol. 97, E54\u2013E58 (2022).","journal-title":"Am. J. Hematol."},{"key":"1129_CR116","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-022-01319-y","volume":"15","author":"S Lee","year":"2022","unstructured":"Lee, S. et al. Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. J. Hematol. Oncol. 15, 103 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"1129_CR117","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/0008-5472.CAN-23-1992","volume":"84","author":"R Marullo","year":"2024","unstructured":"Marullo, R. et al. XPO1 enables adaptive regulation of mRNA export required for genotoxic stress tolerance in cancer cells. Cancer Res. 84, 101\u2013117 (2024).","journal-title":"Cancer Res."},{"key":"1129_CR118","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-20-2306","volume":"26","author":"A Tripathi","year":"2020","unstructured":"Tripathi, A. et al. Dual blockade of c-MET and the androgen receptor in metastatic castration-resistant prostate cancer: a phase I study of concurrent enzalutamide and crizotinib. Clin. Cancer Res. 26, 6122\u20136131 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1129_CR119","doi-asserted-by":"publisher","first-page":"606","DOI":"10.18632\/oncotarget.28758","volume":"16","author":"A Deacon","year":"2025","unstructured":"Deacon, A. et al. Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer. Oncotarget 16, 606\u2013620 (2025).","journal-title":"Oncotarget"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01129-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01129-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01129-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:03:42Z","timestamp":1785758622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01129-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":119,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1129"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01129-8","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"21 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}